Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7319
Buy Now

Market Overview:

The 7 major chemotherapy-induced neutropenia markets reached a value of US$ 371.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 455.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 371.2 Million
Market Forecast in 2034
US$ 455.7 Million
Market Growth Rate 2024-2034 1.88%


The chemotherapy-induced neutropenia market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced neutropenia refers to a serious consequence of cancer chemotherapies, in which the number of neutrophils in the blood drops below a healthy level. This loss of neutrophils results in the disruption of immune defense mechanisms and enhances the likelihood of infections. The common symptoms associated with this ailment include fever, chills, sores in the mouth, cough, difficulty breathing, abdominal or rectal pain, etc. In some cases, patients suffering from the disease may also experience diarrhea, swollen lymph nodes, and urinary symptoms, like burning urination with urgency and frequency. Diagnosing this ailment is typically based on a review of underlying symptoms, patient’s medical history, and laboratory studies. The healthcare professionals may also perform a complete blood count to determine the absolute neutrophil count of the patient. In some cases, additional testing may be utilized to evaluate the underlying cause of chemotherapy-induced neutropenia. This may include a biopsy, in which a sample of the bone marrow is examined under a microscope to identify abnormalities associated with the indications and confirm a diagnosis.

Chemotherapy-Induced Neutropenia Market

The escalating utilization of chemotherapeutic drugs for cancer treatment, which can cause damage to healthy neutrophils and the bone marrow that produces white blood cells, is primarily driving the chemotherapy-induced neutropenia market. Moreover, the widespread adoption of effective drugs, such as granulocyte colony-stimulating factors to boost neutrophil production and help protect against infection, is also bolstering the market growth. In addition to this, the inflating application of disease diagnostic tools, such as a bone marrow aspiration test to measure if the bone marrow is healthy and producing normal amounts of blood cells, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to launch cost-effective injectable treatment alternatives due to quicker onset of action and faster symptom relief. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of pegfilgrastim solutions for treating the ailment, since it can significantly increase peripheral blood neutrophil counts and has low renal clearance, is further expected to drive the chemotherapy-induced neutropenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced neutropenia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chemotherapy-induced neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced neutropenia market in any manner.

Recent Developments:

  • In November 2023, Evive Biotech, a subsidiary of Yifan Pharmaceuticals Co. Ltd., and Acrotech Biopharma declared that on November 16, 2023, the U.S. Food and Drug Administration (FDA) approved Ryzneuta (Efbemalenograstim alfa) to reduce febrile neutropenia in adult patients with non-myeloid malignancies taking myelosuppressive anticancer drugs.


Key Highlights:

  • Half of cancer patients getting chemotherapy have some amount of neutropenia.
  • In the United States, the incidence of chemotherapy-induced neutropenia is 2.4-15.4 cases/million each year.
  • Patients who are over the age of 65 have a higher risk of developing chemotherapy-induced neutropenia.
  • Chemotherapy-induced neutropenia was noted to be associated with platinum-based regimens, taxane-containing regimens, and the number of anticancer drugs in regimens.
  • Cancer patients with diabetes mellitus or hyperglycemia are 32% more likely to develop chemotherapy-induced neutropenia than patients without these two
    diseases.


Drugs:

ROLVEDON (eflapegrastim-xnst) injection is a new formulation of the long-acting granulocyte colony-stimulating factor (G-CSF). Spectrum has been approved to reduce the incidence of infection, as shown by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer medicines that are linked with a clinically significant incidence of febrile neutropenia.

Plinabulin is a selective immunomodulating microtubule-binding drug that stimulates antigen-presenting cells (APCs). It is a new, intravenous-infused, patent-protected, NDA-stage product for preventing chemotherapy-induced neutropenia.

myelo001 is an under-investigational drug by Myelo Therapeutics GmbH. This therapeutic candidate is a small molecule that could provide a cheaper and safer alternative to the standard-of-care G-CSF to prevent and treat chemotherapy-induced neutropenia.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the chemotherapy-induced neutropenia market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the chemotherapy-induced neutropenia market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current chemotherapy-induced neutropenia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Neupogen (Filgrastim) Amgen/Roche
Rolvedon (Eflapegrastim) Hanmi Pharmaceutical/Spectrum Pharmaceuticals
Neulasta (Pegfilgrastim) Amgen/Kyowa Kirin
Plinabulin BeyondSpring Pharmaceuticals
EC-18 Enzychem Lifesciences
myelo001 Myelo Therapeutics GmbH
Plinabulin BeyondSpring Pharmaceuticals Inc.


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the chemotherapy-induced neutropenia market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the chemotherapy-induced neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the chemotherapy-induced neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of chemotherapy-induced neutropenia by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with chemotherapy-induced neutropenia across the seven major markets?
  • What is the size of the chemotherapy-induced neutropenia patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (​2024-2034​) across the seven major markets?
  • What are the key factors driving the epidemiological trend of chemotherapy-induced neutropenia?
  • What will be the growth rate of patients across the seven major markets?
     

Chemotherapy-Induced Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for chemotherapy-induced neutropenia drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced neutropenia market?
  • What are the key regulatory events related to the chemotherapy-induced neutropenia market?
  • What is the structure of clinical trial landscape by status related to the chemotherapy-induced neutropenia market?
  • What is the structure of clinical trial landscape by phase related to the chemotherapy-induced neutropenia market?
  • What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced neutropenia market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More